Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y
Department of Anesthesiology and Intensive Care, Hokkaido University School of Medicine, Sapporo, Japan.
Crit Care Med. 1998 Jan;26(1):184-7. doi: 10.1097/00003246-199801000-00038.
To evaluate the ganciclovir pharmacokinetics and clearance during continuous venovenous hemodiafiltration.
Case report.
General intensive care unit of a tertiary care emergency department.
A 63-yr-old female who has a history of active behçet's disease that has been controlled with oral prednisolone, and who has chronic renal failure.
None.
A 5-mg/kg dosage of ganciclovir was administered intravenously over a 60-min period under continuous venovenous hemodiafiltration. Samples from the arterial and venous blood catheters and from the ultradiafiltrate were collected over the next 12 hrs to calculate pharmacokinetic parameters and clearance of hemodiafiltration. The pharmacokinetic parameters were as follows: half-life of elimination phase 12.6 hrs; total clearance 0.55 mL/min/kg; and volume distribution of steady state 27.07 L. The clearance of hemodiafiltration was 0.63 mL/min/kg.
Continuous venovenous hemodiafiltration is effective in removing ganciclovir from the blood.
评估更昔洛韦在持续静静脉血液透析滤过过程中的药代动力学及清除率。
病例报告。
三级急诊部门的综合重症监护病房。
一名63岁女性，有白塞病活动病史，一直口服泼尼松龙控制病情，患有慢性肾衰竭。
无。
在持续静静脉血液透析滤过期间，60分钟内静脉注射5mg/kg剂量的更昔洛韦。在接下来的12小时内，从动脉和静脉血导管以及超滤液中采集样本，以计算药代动力学参数和血液透析滤过的清除率。药代动力学参数如下：消除相半衰期12.6小时；总清除率0.55mL/（min·kg）；稳态分布容积27.07L。血液透析滤过的清除率为0.63mL/（min·kg）。
持续静静脉血液透析滤过能有效清除血液中的更昔洛韦。
